Publications by authors named "Ana Oaknin"

56Publications

Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change?

ESMO Open 2020 Oct;5(5)

MBBS MA FRCP, The Royal Marsden NHS Foundation Trust nd Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2020-000924DOI Listing
October 2020

Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.

JAMA Oncol 2020 Oct 1. Epub 2020 Oct 1.

Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille-Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Department of Medical Oncology, Aix-Marseille University, Inserm, Centre National de la Recherche Scientifique, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.4515DOI Listing
October 2020

Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives.

Curr Opin Oncol 2020 Sep;32(5):471-480

Gynecologic Oncology Unit and Scientific Directorate, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000658DOI Listing
September 2020

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

N Engl J Med 2019 12 28;381(25):2403-2415. Epub 2019 Sep 28.

From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C.); University of Chicago Medicine (G.F.F.) and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University (D.C.), Chicago, and AbbVie, North Chicago (D.M.S., B.A.B., S.B., C.K.R., P.J.A., M.H.D.) - all in Illinois; NRG Oncology Statistical and Data Center, Roswell Park Cancer Institute, Buffalo (M.F.B.), and Memorial Sloan Kettering Cancer Center, New York (K.B.-M., C.A.) - both in New York; University of Washington-Seattle Cancer Care Alliance, Seattle (E.M.S.); Lillebaelt University Hospital of Southern Denmark, Vejle, and the University of Southern Denmark, Odense (K.D.S.); Prince of Wales Clinical School, University of New South Wales and Royal Hospital for Women (M.F.), and the Northern Cancer Institute (S.B.-H.), Sydney; Jikei University School of Medicine, Tokyo (A. Okamoto), and Aichi Cancer Center Hospital, Nagoya (M.M.) - both in Japan; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Kaplan Medical Center, Rehovot, Israel (N.E.B.-B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (T.L.W.); Texas Oncology, U.S. Oncology Research Network, Fort Worth (N.G.C.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (A. Oaknin); Women and Infants Hospital, Providence, RI (P.A.D.); Penn Medicine, Philadelphia (M.A.M.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.-H.N.); O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham (C.A.L.); Oxford University Hospitals, Oxford, United Kingdom (S.N.); Washington University School of Medicine, St. Louis (A.R.H.); Kaiser Permanente Northern California, San Francisco (R.D.L., M.A.B.); and H.M. Hospitales-Centro Integral Oncológico H.M. Clara Campal, Madrid (J.G.-D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1909707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941439PMC
December 2019

Cervical cancer.

Lancet 2019 01;393(10167):169-182

Department Obstetrics and Gynaecology, University of Cape Town, Cape Town, South Africa; South African Medical Research Council, Gynaecological Cancer Research Centre, Tygerberg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)32470-XDOI Listing
January 2019

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

N Engl J Med 2018 12 21;379(26):2495-2505. Epub 2018 Oct 21.

From the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica, Rome (G.S.) - both in Italy; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (B.-G.K.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (A. Oaknin), and M.D. Anderson Cancer Centre Madrid, Madrid (A.G.-M.) - both in Spain; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, Australia (M.F.); St. Petersburg City Oncology Dispensary, St. Petersburg, Russia (A. Lisyanskaya); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris (A.F., A. Leary), Institut Bergonié, Comprehensive Cancer Center, Bordeaux (A.F.), and Gustave-Roussy Cancer Campus, Villejuif (A. Leary) - all in France; the Netherlands Cancer Institute, Amsterdam (G.S.S.); Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (C.G.), the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London (S.B.), and AstraZeneca, Cambridge (R.B.) - all in the United Kingdom; Princess Margaret Cancer Centre, Toronto (A. Oza); Memorial Sloan Kettering Cancer Center, New York (C.A.); Froedtert and the Medical College of Wisconsin, Milwaukee (W.B.); Women and Infants Hospital, Providence, RI (C.M., P.D.); Dana-Farber Cancer Institute, Boston (J.L.); and AstraZeneca, Gaithersburg, MD (E.S.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810858
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810858DOI Listing
December 2018

The genetic landscape of 87 ovarian germ cell tumors.

Gynecol Oncol 2018 10 28;151(1):61-68. Epub 2018 Aug 28.

Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium; Division of Gynaecological Oncology, Leuven Cancer Institute, Kuleuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183113
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.08.013DOI Listing
October 2018

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

J Minim Invasive Gynecol 2019 Mar - Apr;26(3):492-500. Epub 2018 Jun 13.

Department of Obstetrics and Gynecology (Drs. Gil-Moreno, Carbonell-Socias, Salicrú, Centeno-Mediavilla, Franco-Camps, Pérez-Benavente, and Díaz-Feijoo), Biomedical Research Group in Gynecology (Dr. Colas), and Department of Medical Oncology (Dr. Oaknin), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15534650183031
Publisher Site
http://dx.doi.org/10.1016/j.jmig.2018.06.007DOI Listing
July 2019

[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Rev Esp Patol 2018 Apr - Jun;51(2):84-96. Epub 2018 Jan 17.

Departamento de Anatomía Patológica, Hospital Universitario Ramón y Cajal, IRYCIS y Universidad de Alcalá, CIBERONC, Madrid, España. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.patol.2017.11.002DOI Listing
March 2019

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

Future Oncol 2018 Jul 9;14(17):1669-1678. Epub 2018 Feb 9.

Division of Hematology-Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0646DOI Listing
July 2018

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer.

Int J Gynecol Cancer 2017 02;27(2):258-266

*Gustave Roussy Cancer Campus, Villejuif, France; †Leuven Cancer Institute, Leuven, Belgium; ‡Centre François Baclesse, Caen, France; §Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; ‖Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland; ¶Leeds Cancer Centre, St James University Hospital, Leeds, United Kingdom; #City Clinical Oncology Dispensary, St Petersburg, Russia; **Gartnavel General Hospital, Glasgow, United Kingdom; ††Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; ‡‡Vilnius University Institute of Oncology, Vilnius, Lithuania; §§Oncology Centre of Latvia, Riga East University Hospital, Riga, Latvia; ‖‖Ipsen Innovation, Les Ulis, France; and ¶¶Clatterbridge Cancer Centre, University of Liverpool, Bebington, Merseyside, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000862DOI Listing
February 2017

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

Gynecol Oncol 2015 Jul 26;138(1):18-23. Epub 2015 Apr 26.

University Hospital Leuven, Leuven Cancer Institute, Department of Oncology, KU Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.04.026DOI Listing
July 2015

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Jun 18;73(6):1205-15. Epub 2014 Apr 18.

Clinical Research Unit, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Ctra. Gran Vía, 08907 s/n., Barcelona, Spain,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2457-1DOI Listing
June 2014

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

J Clin Oncol 2014 May 17;32(13):1302-8. Epub 2014 Mar 17.

Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris; Béatrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre Léon Bérard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Klinik für Gynäkologie und Geburtshilfe, Kiel; Alexander Reuss, AGO and Coordinating Center for Clinical Trials, Marburg; Pauline Wimberger, AGO and University of Duisburg-Essen, Essen, Germany; Andres Poveda, Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Instituto Valenciano de Oncologia, Valencia; Ana Oaknin, GEICO and Vall d'Hebron University Hospital, Barcelona, Spain; Gunnar Kristensen, Nordic Society of Gynaecological Oncology (NSGO) and Norwegian Radium Hospital, Oslo, Norway; Roberto Sorio, Multicenter Italian Trials in Ovarian Cancer and Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy; Ignace Vergote, Belgian Gynaecological Oncology Group and University Hospital Leuven, Leuven, Belgium; Petronella Witteveen, Dutch Gynecological Oncology Group and University Medical Center Utrecht, Utrecht, the Netherlands; Aristotelis Bamias, Hellenic Cooperative Oncology Group and University of Athens, Athens, Greece; Deolinda Pereira, GINECO and Instituto Português de Oncologia do Porto, Porto, Portugal; Mansoor Raza Mirza, NSGO and Rigshospitalet, Copenhagen, Denmark; and David Bollag, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.4489DOI Listing
May 2014

Improved survival with bevacizumab in advanced cervical cancer.

N Engl J Med 2014 Feb;370(8):734-43

From the University of California, Irvine, Medical Center, Orange (K.S.T.); Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo (M.W.S., H.H.); Mayo Clinic, Rochester, MN (H.J.L.); Massachusetts General Hospital, Boston (R.T.P.); M.D. Anderson Cancer Center, Houston (L.M.R.); University of Oklahoma, Oklahoma City (L.M.L.); Vall d'Hebron University Hospital, Barcelona (A.O.); University of Cincinnati College of Medicine-Women's Cancer Center at Kettering, Kettering, OH (T.J.R.); Memorial Sloan-Kettering Cancer Center, New York (M.M.L.); Indiana University School of Medicine, Indianapolis (H.E.M.); and the University of Arizona Cancer Center and Creighton University at St. Joseph's Hospital and Medical Center, Phoenix (B.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1309748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094PMC
February 2014

Treatment of metastatic cervical cancer: future directions involving targeted agents.

Crit Rev Oncol Hematol 2013 Mar 9;85(3):303-14. Epub 2012 Aug 9.

Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2012.07.006DOI Listing
March 2013

SEOM guidelines for cervical cancer.

Clin Transl Oncol 2012 Jul;14(7):516-9

Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-012-0834-yDOI Listing
July 2012

SEOM guidelines for endometrial cancer.

Clin Transl Oncol 2012 Jul;14(7):512-5

Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-012-0833-zDOI Listing
July 2012

Angiosarcoma of the ovary: is it always a lethal disease?

J Clin Oncol 2010 Nov 7;28(33):e675-7. Epub 2010 Sep 7.

Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.30.0830DOI Listing
November 2010

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.

Invest New Drugs 2011 Dec 10;29(6):1406-13. Epub 2010 Jul 10.

Instituto Catalán de Oncología, Ctra. Gran Vía, s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9488-1DOI Listing
December 2011

Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.

Expert Rev Anticancer Ther 2010 Jun;10(6):795-805

Gynecological Cancer Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.10.59DOI Listing
June 2010

CA-125 response patterns in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD).

Int J Gynecol Cancer 2010 Jan;20(1):87-91

Gynecology Cancer Unit, Oncology Department, Vall d'Hebron University Hospital, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/IGC.0b013e3181c16ba1DOI Listing
January 2010

Human papillomavirus vaccine and cervical cancer prevention.

Clin Transl Oncol 2008 Dec;10(12):804-11

Instituto Catalán de Oncología, Hospital Durán i Reynals, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-008-0293-7DOI Listing
December 2008